HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

IDEAYA Biosciences Secures IND Clearance for IDE275 (GSK959) to Initiate Phase 1 Trial in MSI-High Solid Tumors

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

Home
/
update
/
details

Precision Oncology Innovations Unveiled at AACR 2024: Predicine and Guardant Health Lead the Way

NextEdge Admin

05 Apr 2024

3 min 55 sec

Predicine a frontrunner in precision oncology, has announced its presentation of data from 15 circulating tumor DNA (ctDNA) studies at AACR 2024. These findings underscore the clinical efficacy of Predicine’s genomic and epigenomic liquid biopsy solutions across patient selection, disease monitoring, and elucidating disease mechanisms. The forthcoming data signifies a substantial stride towards the practical application of Predicine’s state-of-the-art liquid biopsy technology in personalized cancer care, clinical trials, and advancing Companion Diagnostics (CDx).

The studies to be unveiled at the conference highlight the unique benefits of PredicineBEACON™ and methylation-based PredicineALERT™ MRD, showcasing their utility in biomarker discovery, therapy selection, response monitoring, and analyzing drug resistance mechanisms. Predicine operates as a global molecular insights company committed to propelling precision medicine in oncology and infectious disease diagnostics. Through its development of proprietary cell-free DNA and RNA-based liquid biopsy technologies, Predicine aims to enable minimally invasive molecular diagnosis for early cancer detection, treatment selection, therapy response, minimal residual disease monitoring, and tracking disease progression. With business operations spanning across several key locations worldwide, Predicine collaborates with leading biopharma companies, institutions, and governments to advocate for personalized healthcare on a global scale.

Meanwhile, Guardant Health, another leader in precision oncology, has also announced its presentation of data from nine studies focusing on advances in methylation-based epigenomic analysis at the AACR 2024 Annual Meeting. The presentations will highlight the utility of the Guardant Infinity™ platform across various aspects of cancer care, including predictive histologic subtyping, cardiac adverse event prediction, and minimal residual disease detection in breast cancer using Guardant Reveal. Helmy Eltoukhy, Guardant Health chairman and co-CEO, emphasized the potential of epigenomic analysis to advance cancer research, expand patient eligibility for clinical trials, and contribute to targeted therapy development.

The Guardant Infinity smart liquid biopsy platform integrates genomic and epigenomic profiling to provide comprehensive insights into cancer, aiding researchers, and clinicians in characterizing and quantifying tumors, understanding tumor heterogeneity, disease progression, and treatment response. These epigenomic insights enable more personalized treatment strategies, enhancing accuracy in minimal residual disease detection and monitoring, identifying new patients, and predicting responses to therapy through novel epigenomic biomarkers. Guardant Health, since its inception in 2012, has been dedicated to transforming patient care by providing critical insights into disease drivers through advanced blood and tissue tests, real-world data, and AI analytics, ultimately improving outcomes across all stages of cancer care.